Side-by-side · Research reference

IGF-DESvsPT-141

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED8/60 cited

BFDA-ApprovedHUMAN-REVIEWED13/41 cited

IGF-DES

IGF-1 Analogue · Truncated N-Terminal

~10×Potency vs IGF-1

ReducedIGFBP binding

ResearchStatus

Injection (local or systemic) · Research protocols onlyBredehöft 2008

PT-141

MC4R Agonist · FDA-Approved (HSDD)

1.75 mgPer doseVYLEESI (bremelanotide injecti 2019

Pre-sexTimingVYLEESI (bremelanotide injecti 2019

~2.7 hrHalf-lifeVYLEESI (bremelanotide injecti 2019

SQ · Abdomen / thigh · ≥45 min before sex

01Mechanism of Action

Parameter

IGF-DES

PT-141

Primary target

IGF-1 receptor (IGF1R)Shields 2007

Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023 VYLEESI (bremelanotide injecti 2019

Pathway

IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation

MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023

Downstream effect

Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation

Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015

Feedback intact?

Unknown — no human endocrine feedback data

—

Origin

Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008

Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019

Antibody development

—

02Dosage Protocols

Parameter

IGF-DES

PT-141

Research dose range

10–100 ng/mL (in vitro); μg doses (animal models)

Highly context-dependent; no standardized human protocol.

—

Route

Subcutaneous or intramuscular (local injection favored)

Local delivery maximizes tissue-specific uptake.

—

Frequency

Variable — daily to multiple times daily in research

PRN, max 8 doses / month

Evidence basis

Animal models + in vitro only

FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019 Clayton 2015

Human data

None — no clinical trials

—

Half-life

Shorter than IGF-1 due to reduced IGFBP binding

Rapid tissue uptake, limited systemic circulation.

~2.7 hrVYLEESI (bremelanotide injecti 2019

Standard dose

—

1.75 mg SQVYLEESI (bremelanotide injecti 2019

Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.

Lower / starter dose

—

1 mg (off-label)

Duration

—

PRN; reassess if no benefit after 8 doses

Reconstitution

—

Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.

Timing

—

≥45 min before sexual activity

03Metabolic / Fat Loss Evidence

Parameter

IGF-DES

PT-141

Primary mechanism

Indirect via muscle hypertrophy → metabolic rate elevation

—

Direct lipolysis

Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic

—

Prostate model

Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002

Context-specific anti-proliferative effect, not fat loss.

—

04Side Effects & Safety

Parameter

IGF-DES

PT-141

Hypoglycemia risk

Theoretical — IGF-1 axis enhances glucose uptake

—

Mitogenic risk

Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002

—

Injection site reaction

Expected — erythema, irritation, local swelling

Erythema, mild pain

Edema / Fluid retention

Possible via sodium retention (IGF-1 axis effect)

—

Human safety data

Absent — no human trials, all effects theoretical or extrapolated

—

Unknown long-term effects

No chronic dosing studies in humans; endocrine, metabolic consequences unknown

—

Nausea

—

Common (~40%); often transientVYLEESI (bremelanotide injecti 2019

Flushing

—

Common, transient

Headache

—

Common

Hyperpigmentation (focal)

—

Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019

Hypertension (transient)

—

Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019

Pregnancy / OB

—

Contraindicated

Cardiovascular disease

—

Use caution; transient BP rise

Absolute Contraindications

IGF-DES

·Active malignancy or history of cancer (mitogenic risk)
·Pregnancy / lactation (no safety data)
·Hypoglycemia disorders

PT-141

·Uncontrolled hypertension
·Known cardiovascular disease (caution)
·Pregnancy

Relative Contraindications

IGF-DES

·Diabetes mellitus (unpredictable glucose effects)
·Renal or hepatic impairment (clearance unknown)
·Edema-prone conditions (heart failure, nephrotic syndrome)

PT-141

·Pre-existing hyperpigmentation disorders
·MC4R-pathway-dependent psychiatric conditions

05Administration Protocol

Parameter

IGF-DES

PT-141

1. Research context only

Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.

Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.

2. Reconstitution (if lyophilized)

Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.

SQ — abdomen or thigh.

3. Injection site

Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.

≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.

4. Timing

Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.

Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.

5. Needle gauge

27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.

Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.

6. Monitoring

Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.

—

06Stack Synergy

IGF-DES

+ BPC-157

Moderate

View BPC-157 →

Des(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.

Des(1-3)IGF-1: Research dose post-workout (local IM)
BPC-157: 250–500 mcg SQ, daily or twice daily
Frequency: Daily or per research protocol
Primary benefit: Accelerated muscle repair, enhanced hypertrophy, connective tissue support

+ TB-500

Moderate

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.

Des(1-3)IGF-1: Research dose post-workout (local IM)
TB-500: 2–5 mg SQ, 2× weekly
Frequency: Per research cycle
Primary benefit: Muscle hypertrophy, injury recovery, vascular support

PT-141

— no documented stacks